Skip to content
Disclosery

GREAT POINT PARTNERS LLC

Follow

13F filer, CIK 1281446, Greenwich, CT

GREAT POINT PARTNERS LLC reported $435,118,234 across 42 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 53.63% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001172661-26-002272

Period
2026-03-31
Reported value
$435M
Holdings
42
Top 10 weight
53.63%
New
21
Sold out
8

Largest buys vs the previous quarter

SecurityShares changeApprox. value
SLGLnew+274,363$21.7M
ALMSnew+856,061$18.9M
DRUGnew+220,000$16.1M
ANNXnew+2,500,000$13.8M
ZBIOnew+524,066$10.2M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
IRONexited-250,000-$19.9M
RAPTexited-581,187-$19.7M
SLNOexited-400,000-$18.5M
DNTHexited-350,000-$14.4M
FULCexited-800,000-$9.05M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001172661-26-002272, largest first. % of portfolio is the value over $408,269,707, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 304,000 shares; 2025Q4: 374,000 shares; 2026Q1: 374,000 shares 374,000$31.5M7.71%0Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,370,107 shares; 2026Q1: 1,750,000 shares 1,750,000$31.2M7.65%+379,893Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,263,672 shares; 2024Q4: 3,170,194 shares; 2025Q1: 3,170,194 shares; 2025Q2: 3,170,194 shares; 2025Q3: 3,815,930 shares; 2025Q4: 3,815,930 shares; 2026Q1: 4,215,930 shares 4,215,930$25.1M6.14%+400,000Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,811,996 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,700,000 shares; 2025Q4: 1,750,000 shares; 2026Q1: 1,750,000 shares 1,750,000$24.3M5.96%0Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 300,000 shares; 2025Q4: 210,732 shares; 2026Q1: 316,453 shares 316,453$22.8M5.58%+105,721Timeline
SLGLSOL-GEL TECHNOLOGIES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 274,363 shares 274,363$21.7M5.32%newTimeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 856,061 shares 856,061$18.9M4.62%newTimeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 220,000 shares 220,000$16.1M3.93%newTimeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,500,000 shares 2,500,000$13.8M3.39%newTimeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,299,503 shares; 2024Q4: 1,787,003 shares; 2025Q1: 1,014,367 shares; 2025Q2: 323,170 shares; 2025Q3: not reported; 2025Q4: 685,632 shares; 2026Q1: 675,000 shares 675,000$13.6M3.33%-10,632Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 375,000 shares; 2025Q2: 262,176 shares; 2025Q3: 500,000 shares; 2025Q4: 750,000 shares; 2026Q1: 545,625 shares 545,625$13.6M3.32%-204,375Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 498,054 shares; 2025Q3: 632,599 shares; 2025Q4: 806,273 shares; 2026Q1: 964,462 shares 964,462$13.6M3.32%+158,189Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 800,000 shares; 2026Q1: 800,198 shares 800,198$10.5M2.56%+198Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 524,066 shares 524,066$10.2M2.51%newTimeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,004,291 shares; 2024Q4: 442,761 shares; 2025Q1: 470,964 shares; 2025Q2: 485,859 shares; 2025Q3: 446,814 shares; 2025Q4: 350,000 shares; 2026Q1: 500,000 shares 500,000$10.1M2.47%+150,000Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares 500,000$9.32M2.28%newTimeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 248,168 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 979,534 shares; 2026Q1: 1,334,130 shares 1,334,130$9.14M2.24%+354,596Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 514,659 shares; 2024Q4: 228,803 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 183,330 shares; 2025Q4: 183,330 shares; 2026Q1: 183,330 shares 183,330$8.99M2.2%0Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,200,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 1,200,000 shares 1,200,000$8.69M2.13%0Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 199,348 shares 199,348$8.02M1.96%newTimeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 325,000 shares; 2026Q1: 325,000 shares 325,000$7.47M1.83%0Timeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 300,000 shares 300,000$7.4M1.81%newTimeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,350,000 shares 1,350,000$7.14M1.75%newTimeline
SCYXSCYNEXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 7,554,347 shares 7,554,347$6.93M1.7%newTimeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,405,757 shares 3,405,757$5.96M1.46%newTimeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 6,934,982 shares; 2024Q4: 4,683,711 shares; 2025Q1: 4,683,711 shares; 2025Q2: 4,683,711 shares; 2025Q3: 4,683,711 shares; 2025Q4: 4,683,711 shares; 2026Q1: 2,238,496 shares 2,238,496$5.86M1.44%-2,445,215Timeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 842,106 shares 842,106$5.86M1.44%newTimeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 808,032 shares; 2026Q1: 1,020,489 shares 1,020,489$5.38M1.32%+212,457Timeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 796,558 shares; 2025Q3: 796,558 shares; 2025Q4: 796,558 shares; 2026Q1: 796,558 shares 796,558$5.24M1.28%0Timeline
TENXTENAX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 327,307 shares 327,307$5.23M1.28%newTimeline
PMNPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 371,402 shares 371,402$4.72M1.16%newTimeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 634,032 shares; 2026Q1: 300,000 shares 300,000$4.26M1.04%-334,032Timeline
IMMXIMMIX BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares 350,000$3.19M0.78%newTimeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 621,894 shares; 2025Q1: 833,042 shares; 2025Q2: 3,033,462 shares; 2025Q3: 2,451,809 shares; 2025Q4: 951,809 shares; 2026Q1: 951,809 shares 951,809$2.9M0.71%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,105 shares; 2025Q4: 82,800 shares; 2026Q1: 82,800 shares 82,800$2.34M0.57%0Timeline
HUMAHUMACYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,750,000 shares 3,750,000$2.28M0.56%newTimeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 124,666 shares; 2026Q1: 124,666 shares 124,666$1.86M0.46%0Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 50,000 shares 50,000$1.77M0.43%newTimeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 324,340 shares 324,340$1.48M0.36%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
IBRXIMMUNITYBIO INC COMput3,000,800$23Mnew
GALTGALECTIN THERAPEUTICS INC COMMON STOCKcall800,000$2.23Mnew
AVXLANAVEX LIFE SCIENCES CORP COM NEWcall521,300$1.6Mnew

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
IRONDISC MEDICINE INC250,000$19.9Mshares
RAPTRAPT THERAPEUTICS INC581,187$19.7Mshares
SLNOSOLENO THERAPEUTICS INC400,000$18.5Mshares
DNTHDIANTHUS THERAPEUTICS INC350,000$14.4Mshares
FULCFULCRUM THERAPEUTICS INC800,000$9.05Mshares
UPBUPSTREAM BIO INC300,000$8.14Mshares
RAREULTRAGENYX PHARMACEUTICAL IN300,000$6.9Mshares
SANASANA BIOTECHNOLOGY INC700,000$2.85Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-26-002272 base2026-05-15acceptance time not in the bulk data set